Abstract
Bladder cancer is the second most common malignancy of the urogenital region. The majority of bladder cancer deaths occur as a consequence of metastatic disease. Microvessel density (MVD), a surrogate marker for angiogenesis, has been shown to be predictive of progression and poor prognosis. The aim of this study was to evaluate the predictive value and prognostic significance of angiogenesis in human non muscle invasive bladder cancer (NMIBC) treated by BCG immunotherapy. The frozen sections of 28 non muscle invasive bladder cancer specimens were stained with CD34 antibody to label the vascular endothelium using the standard streptavidin-biotin immunoperoxidase method. Angiogenic activity was measured using microvessel count determined by the expression of vascular markers CD34.The prognostic significance of tumor stage, grade, loci number, tumor size, age and CD34 expression in determining the risk for recurrence was studied with both univariate and multivariate methods of analysis. According to univariate analysis of the prognostic significance for tumor stage, grade, tumor size, loci number, age and CD34 expression, in patients with NMIBC, the pT1 stage and high grade seem to be associated in a statistically significant man...Continue Reading
References
Feb 21, 1992·Science·C de VriesL T Williams
Feb 1, 1992·Journal of Clinical Pathology·I KuzuD Y Mason
Jan 3, 1991·The New England Journal of Medicine·N WeidnerJ Folkman
Jul 1, 1991·American Journal of Clinical Pathology·S T TraweekH Battifora
Dec 1, 1994·British Journal of Urology·A J DickinsonA L Harris
Jul 1, 1995·The Journal of Urology·T M JaegerP R Carroll
Nov 1, 1995·Journal of the National Cancer Institute·B H BochnerP W Nichols
Feb 1, 1995·Nature Medicine·L HolmgrenJ Folkman
Nov 11, 1993·International Journal of Cancer. Journal International Du Cancer·G GaspariniP Bevilacqua
May 1, 1996·British Journal of Urology·H H KöhlerA Bittinger
Mar 1, 1996·British Journal of Urology·E A PhilpM W Reed
Aug 28, 1998·The Journal of Urology·J P SteinR J Cote
Sep 29, 1998·The Journal of Urology·C P DinneyH B Grossman
Feb 6, 1999·European Urology·K YörükogluZ Kirkali
Jul 22, 1999·Urology·E OzerZ Kirkali
Apr 19, 2000·The American Journal of Dermatopathology·L SchaererW Kempf
May 19, 2001·Urology·O SağolZ Kirkali
Jul 18, 2001·Pathology Oncology Research : POR·M TenderendaR Kubiak
Jul 27, 2001·Virchows Archiv : an International Journal of Pathology·P KorkolopoulouP Davaris
Apr 23, 2002·BJU International·J A Martínez-PiñeiroUNKNOWN for CUETO (Club Urológico Español de Tratamiento Oncológico)
Apr 2, 2003·European Urology·Fabien SaintDominique K Chopin
Citations
Mar 22, 2013·PloS One·Yasuyoshi MiyataHideki Sakai
Dec 18, 2013·Urologic Oncology·Evanguelos XylinasShahrokh F Shariat
Dec 30, 2015·European Journal of Cancer Care·M A SkrzypczykJ Dobruch
Nov 6, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiaojing XingHuinan Ye
May 31, 2014·BioMed Research International·Shumin WangMariko Murata
Apr 18, 2015·The Urologic Clinics of North America·Ilaria LuccaShahrokh F Shariat
Jul 8, 2016·Orthopaedic Surgery·Xing ZhouXin Shi
May 18, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Satiesh Kumar RamadassBalaraman Madhan
Oct 19, 2016·In Vitro Cellular & Developmental Biology. Animal·Jonas Magno Santos CesárioHumberto Dellê
Dec 30, 2017·Oncotarget·Wan-Qi LvCui-Ying Li
Jan 22, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Volkan SenUgur Mungan
Sep 24, 2020·BMC Cancer·Yiyang WangRenfu Chen
Feb 22, 2013·Oncology Letters·Wei WangQiang Ding
Apr 22, 2016·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Antoine G van der Heijden, Mark W Dewhirst
Feb 25, 2021·Biomedical Materials·Yonggang WangBaigang Zhang